CLINICAL_TRIALS trial_result · 2018-12-31

Clinical Trial Update: A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

A 52-week Phase 3 safety study of TD-4208 in chronic obstructive pulmonary disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Mylan Inc. | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2018-12-31